| Breakdown | Mar 2025 | Jun 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 52.53M | 166.20M | 756.22M | 619.07M | 261.54M |
| Gross Profit | 78.00K | -52.45M | 53.06M | 77.76M | 26.91M |
| EBITDA | 6.28M | -86.16M | 20.68M | 33.85M | 14.98M |
| Net Income | 8.84M | -88.34M | 11.32M | 14.86M | 1.78M |
Balance Sheet | |||||
| Total Assets | 484.74M | 488.72M | 694.85M | 239.88M | 216.86M |
| Cash, Cash Equivalents and Short-Term Investments | 11.84M | 11.24M | 11.21M | 11.23M | 1.14M |
| Total Debt | 111.29M | 115.17M | 51.92M | 74.53M | 102.94M |
| Total Liabilities | 301.33M | 300.81M | 460.02M | 136.29M | 128.12M |
| Stockholders Equity | 183.40M | 187.91M | 234.82M | 103.59M | 88.74M |
Cash Flow | |||||
| Free Cash Flow | 11.62M | -131.36M | -118.79M | 18.16M | -6.90M |
| Operating Cash Flow | 11.62M | -131.36M | -118.56M | 21.73M | 9.32M |
| Investing Cash Flow | -7.60M | -31.78M | 3.37M | -10.63M | 23.99M |
| Financing Cash Flow | -4.19M | 162.43M | 105.05M | -30.08M | -34.10M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
62 Neutral | ― | 6.16 | ― | ― | 348.82% | ― | |
43 Neutral | ₹111.74M | 6.21 | ― | ― | -53.77% | ― | |
43 Neutral | ₹20.22M | -29.95 | ― | ― | ― | ― |
Vaxtex Cotfab’s board has approved a major increase in its authorised share capital from ₹19 crore to ₹500 crore and plans to amend its Memorandum of Association accordingly, signalling preparations for substantial future equity issuance subject to shareholder approval. The board also cleared changes to the company’s main object clause and its name to better reflect its core business, sought higher borrowing powers and an expanded ₹500 crore limit for loans, investments, guarantees and securities, appointed Dhiraj Mishra as an additional executive director, and set the groundwork for an Extraordinary General Meeting on 27 February 2026 to seek shareholder approvals for these strategic shifts.
Vaxtex Cotfab Limited’s board has approved a significant expansion of its financial and corporate framework, proposing to increase its authorised share capital from ₹19 crore to ₹500 crore and raising its limits for investments, loans, guarantees and securities up to ₹500 crore, alongside higher borrowing powers, all subject to shareholder and regulatory approvals. The board also cleared changes to the company’s main object clause, name and other provisions of its Memorandum and Articles of Association, appointed Dhiraj Mishra as an additional executive director, and set an Extraordinary General Meeting for 27 February 2026 to seek shareholder consent, signalling an ambitious scale-up and strategic repositioning that could materially affect its capital structure, governance and future growth plans.
Vaxtex Cotfab Limited has announced that its Board of Directors, at a meeting held on 24 December 2025, approved requests from certain existing shareholders—Mr. Khushant Gupta, Mr. Mithleshkumar Agrawal, Qmin Industries Limited and Vax Enterprises Private Limited—to reclassify their status from the promoter category to the public shareholder category, subject to approval by the National Stock Exchange of India Limited. The reclassification, once cleared by the exchange, will alter the company’s shareholding structure by reducing the promoter group and increasing the public float, a move that could have implications for corporate control, governance dynamics and the stock’s liquidity profile for investors.